News
  Date Title View
Sep 1, 2015
BURLINGTON, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for FX006, Flexion's late-stage, lead drug candidate that is designed as a treatment for the more than four million U.S. patients receiving intra-articular ...
Aug 6, 2015
Recent HighlightsAdvanced FX006, company's lead program, for the treatment of moderate to severe osteoarthritis (OA) pain by completing patient enrollment in Phase 3 clinical trial ahead of schedule and preparing to announce top-line pivotal data from Phase 2b clinical trial in September (also ahead of schedule)Added Patheon as a contract manufactu...
Aug 4, 2015
Non-dilutive debt financing provides funding for manufacturing expansion for company's Phase 3 lead clinical candidate, FX006, for moderate to severe osteoarthritis (OA) pain BURLINGTON, Mass., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it entered into a syndicated senior secured term loan fa...
Aug 4, 2015
- Adding Patheon as a contract manufacturer, in addition to Evonik Corporation, bolsters manufacturing capacity for planned commercialization of company's lead program BURLINGTON, Mass., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced it has entered into a strategic manufacturing and supply agreement w...
Jul 30, 2015
BURLINGTON, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its second-quarter 2015 financial results on Thursday, August 6, 2015, at 4:30 p.m. ET. The dial-in number for the conference call is (855) 770-0022 for domestic participants and...
Jul 29, 2015
With rapid enrollment in Phase 3 trial, the company expects to report topline data in first quarter of 2016, ahead of scheduleTopline data from ongoing pivotal Phase 2b clinical trial also expected to be reported earlier than planned BURLINGTON, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced th...
Jun 3, 2015
BURLINGTON, Mass., June 3, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that a manuscript describing final study results from a completed Phase 2b clinical trial of FX006, an intra-articular (IA) sustained release corticosteroid for the treatment of osteoarthritis (OA), has been published online1 in the Journal ...
May 7, 2015
Key HighlightsAnnounced a U.S. Department of Defense (DoD) grant worth approximately $2 million to conduct a Phase 2 clinical trial to study lead compound FX006 in active military and medically retired veterans with post-traumatic osteoarthritis (OA)Advanced FX006 by initiating Phase 3 clinical trial on schedule and completing enrollment in pivotal...
Apr 30, 2015
BURLINGTON, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first-quarter 2015 financial results on Thursday, May 7, 2015, at 4:30 p.m. ET. The dial-in number for the conference call is (855) 770-0022 for domestic participants and (9...
Apr 29, 2015
BURLINGTON, Mass., April 29, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Department of Defense ("DoD") awarded the company a grant1 worth approximately $2 million to conduct a Phase 2 clinical trial investigating FX006 as treatment for osteoarthritis ("OA") pain in active military and medically re...
FirstPrevious ...
10
... NextLast
= add release to Briefcase